Editas Medicine (EDIT) Debt Ratio (2016 - 2025)
Editas Medicine's (EDIT) quarterly Debt Ratio came in at 0.31 in Q4 2025, up 86.86% year-on-year from 0.17 in Q4 2024, and up 7.31% on a QoQ basis from 0.29 in Q3 2025.
Editas Medicine (EDIT) Debt Ratio (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 4 years of Debt Ratio data on file, last reported at 0.31 in Q4 2025.
- On a quarterly basis, Debt Ratio rose 86.86% year-over-year to 0.31 in Q4 2025; TTM through Dec 2025 was 0.31, a 86.86% increase from a year earlier, with the FY2025 full-year figure at 0.31, up 86.86% from the prior year.
- Debt Ratio for Q4 2025 stood at 0.31, up from 0.29 in the prior quarter.
- Over the last five years, Debt Ratio for EDIT reached as high as 0.31 in Q4 2025 and fell as low as 0.17 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - | 0.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.31 |
| Sep 30, 2025 | 0.29 |
| Jun 30, 2025 | 0.27 |
| Mar 31, 2025 | 0.21 |
| Dec 31, 2024 | 0.17 |
| Dec 31, 2017 | 0.02 |
| Jun 30, 2017 | 0.04 |
| Mar 31, 2017 | 0.04 |
| Dec 31, 2016 | 0.04 |